Table 1.

Demographics of patients and relevant information for ¹¹¹In-capromab pendetide SPECT/CT studies, including prescan Gleason scores. The lymph node uptake assessment by SPECT/CT studies is listed, and the cases that need clarifications are explained in the footnotes.

	SPECT/MDCT	SPECT/(lowmA) CT
Pre-scan Gleason score		3+4 (2)
	3+3 (5)	4+3 (2)
	3+4 (7)	6 (2)
	4+3 (5)	7 (2)
	5+4 (2)	8 (2)
	5+5 (1)	9 (1)
	N/A (0)	N/A (6)a
Pre-scan PSA (ng/ml)	0-5 (4)	0-5 (9)
	5-10 (6)	5-10 (3)
	10-15 (5)	10-20 (2)
	15-20 (2)	20 (3)
	20 (4)	N/A (1)b
LN assessmentc	LN positive (9)d	LN positive (3)e
	LN negative (12)f	LN negative (15)g
Total	21	17

^aGleason score was not archived when the data were reviewed. Single digit scores are combined Gleason grades.

^bPrescan PSA was not archived when the data were reviewed.

^cOnly suspicious lymph node uptake is considered for this assessment.

^dOne case was pathologically confirmed false positive. The others did not have other definitive confirmation.

^eNo definitive pathologic confirmation was made.

^fOne case was pathologically confirmed false negative. Two were pathologically confirmed true negatives.

^gOne case was LN (obturator) positive by magnetic resonance studies.